Day: December 30, 2021

Mesoblast Provides Update Following Meeting With FDA’s OTAT on Remestemcel-L for Children With Acute Graft Versus Host Disease

Mesoblast Provides Update Following Meeting With FDA’s OTAT on Remestemcel-L for Children With Acute Graft Versus Host Disease

Key Points: Meeting held with the US Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) to address potency assay and chemistry, manufacturing and controls (CMC) items identified in the complete response letter (CRL) for remestemcel-L in the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) in children OTAT indicated that Mesoblast’s approach to address the outstanding CMC items is reasonable OTAT indicated that the in vitro immunomodulatory activity Mesoblast intends to measure for potency is a reasonable critical quality attribute (CQA) for the product, and the relevance of this activity to clinical outcomes should be established Mesoblast has now generated substantial new data that it believes establish the relevance of the proposed in vitro immunomodulatory activity of remestemcel-L...

Continue reading

NorthWest Announces Annual Grant of Stock Options and Restricted Share Units

NorthWest Announces Annual Grant of Stock Options and Restricted Share Units

VANCOUVER, British Columbia, Dec. 30, 2021 (GLOBE NEWSWIRE) — NorthWest Copper (“NorthWest” or the “Company”) (TSX-V:NWST, OTCQX:NWXCC) announces that it has granted 3,575,000 Stock Options to directors, certain employees and consultants, and 1,175,000 Restricted Share Units (“RSUs”) to certain employees and consultants pursuant to its Stock Option and RSU Plans. The Stock Options have an exercise price of $0.80 and have a range of vesting periods over three years and expire after five years. The RSUs are payable in common shares of the Company on exercise, have a range of vesting periods over three years and must be redeemed within 30 days of December 29, 2024, or they expire. About NorthWest Copper: NorthWest is a new copper-gold explorer and developer with an exciting pipeline of projects in British Columbia. With a robust portfolio...

Continue reading

Q-Gold Announces Flow-Through Financing

Q-Gold Announces Flow-Through Financing

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES (All figures in Canadian dollars unless otherwise stated) TORONTO, Dec. 30, 2021 (GLOBE NEWSWIRE) — Q-Gold Resources Ltd (TSXV: QGR, OTC: QGLDF, FRA: QX9G) (“Q-Gold” or the “Company”) is pleased to announce it is initiating a non-brokered flow-through financing (the “Offering”). The Offering will consist of up to of 9,090,910 flow-through units (within the meaning of subsection 66(15) of the Income Tax Act (Canada)) priced at $0.11 per flow-through unit (the “Offering Price”) for gross proceeds of up to $1,000,000. Each flow-through unit will consist of one flow-through common share of the Company and one-half non-flow-through share purchase warrant. Each whole warrant will entitle the holder to acquire one common share of the Company...

Continue reading

Honey Badger Silver Announces Grant of Stock Options

Honey Badger Silver Announces Grant of Stock Options

TORONTO, Dec. 30, 2021 (GLOBE NEWSWIRE) — Honey Badger Silver Inc. (TSX-V: TUF) (“Honey Badger Silver” or the “Company”) announces that the Board of Directors has approved the grant of stock options to directors, officers, employees and consultants of the Company for the purchase of up to 4,809,800 shares in the Company exercisable at a price of $0.075 for a period of five years from the date of grant. The grant is pursuant and subject to the terms and conditions of the Company’s existing stock option plan and is subject to the approval of the TSX Venture Exchange and all regulatory requirements. ON BEHALF OF THE BOARD Chad WilliamsExecutive Chairman and Director About Honey Badger Silver Inc. Honey Badger Silver is a Canadian Silver company based in Toronto, Ontario focused on the acquisition, development and integration of accretive...

Continue reading

Jourdan Announces $2,000,000 Private Placement Flow-Through Financing

Jourdan Announces $2,000,000 Private Placement Flow-Through Financing

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Dec. 30, 2021 (GLOBE NEWSWIRE) — Jourdan Resources Inc. (TSX-V: JOR) (“Jourdan” or the “Company”) announces that it intends to complete a best efforts non-brokered private placement flow-through financing of up to 40,000,000 units (each, a “Unit”) at a price of $0.05 per Unit for gross proceeds of up to $2,000,000 (the “Offering”). Each Unit will be issued on a “flow-through basis” and will consist of one common share of the Company and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder to acquire one additional common share of the Company at an exercise price of $0.08 for a period of 24 months from issuance. Closing of the Offering is expected to occur on or about...

Continue reading

CTO Realty Growth Announces Acquisition of a Grocery-Anchored Retail Property in Atlanta, Georgia and Sale of Its Downtown Daytona Beach Land Parcel

CTO Realty Growth Announces Acquisition of a Grocery-Anchored Retail Property in Atlanta, Georgia and Sale of Its Downtown Daytona Beach Land Parcel

DAYTONA BEACH, Fla., Dec. 30, 2021 (GLOBE NEWSWIRE) — CTO Realty Growth, Inc. (NYSE: CTO) (the “Company” or “CTO”) today announced it has acquired Phase I of The Exchange at Gwinnett, a grocery-anchored retail property in the Buford submarket of Atlanta, Georgia (the “Property”) for $34.0 million. The purchase price represents a going-in cap rate within the range of the Company’s guidance for initial cash yields. The Company also announced the sale of a vacant six-acre development land parcel in downtown Daytona Beach, Florida for $6.3 million. “Phase I of The Exchange at Gwinnett is an excellent opportunity for us to acquire a high-quality, newly built grocery-anchored property in one of the region’s fastest growing retail corridors and now makes Atlanta the largest market in our portfolio based on annualized base rent,” said...

Continue reading

Dentsply Sirona to Present at the 40th Annual J.P. Morgan Healthcare Conference

Dentsply Sirona to Present at the 40th Annual J.P. Morgan Healthcare Conference

CHARLOTTE, N.C., Dec. 30, 2021 (GLOBE NEWSWIRE) — DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY) announced today that the Company will participate virtually in the 40th Annual J.P. Morgan Healthcare Conference. Don Casey, Chief Executive Officer, is scheduled to present on Wednesday, January 12, 2022 at 11:15 am ET. A live audio webcast and presentation materials will be available through the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com. A replay of the webcast will be available for 30 days following the presentation. About Dentsply Sirona Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with a 134-year history of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and...

Continue reading

Assure to Participate in the AlphaNorth Capital Conference

Assure to Participate in the AlphaNorth Capital Conference

DENVER, Dec. 30, 2021 (GLOBE NEWSWIRE) — Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM; TSXV: IOM), a provider of intraoperative neuromonitoring services (“IONM”), announced that it is scheduled to present at the AlphaNorth Capital Investment Conference on March 25-27, 2022. The event introduces growth-stage companies in the technology and healthcare sectors to active top-level capital finance individuals at scheduled in-person one-on-one meetings. Assure Holdings Issues Shares to Complete Consideration for Neuro-Pro AcquisitionThe Company is pleased to announce that it has entered into an agreement with the principals of Neuro-Pro Monitoring LLC (“Neuro-Pro”) for the issuance of an aggregate of 100,000 common shares to such persons in respect of its remaining share consideration obligation in connection with...

Continue reading

SomaLogic to Participate in the 40th Annual J.P. Morgan Healthcare Conference

SomaLogic to Participate in the 40th Annual J.P. Morgan Healthcare Conference

BOULDER, Colo., Dec. 30, 2021 (GLOBE NEWSWIRE) — SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the upcoming 40th Annual J.P. Morgan Healthcare Conference. SomaLogic management is scheduled to present on Tuesday, January 11, 2022, at 11:15 a.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://investors.somalogic.com. About SomaLogicSomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users,...

Continue reading

Silk Road Medical to Present at the 40th Annual J.P. Morgan Healthcare Conference

Silk Road Medical to Present at the 40th Annual J.P. Morgan Healthcare Conference

SUNNYVALE, Calif., Dec. 30, 2021 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming 40th Annual J.P. Morgan Healthcare Conference. Silk Road Medical’s management is scheduled to present on Wednesday, January 12, 2022 at 3:45 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: https://investors.silkroadmed.com/.  About Silk Road MedicalSilk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.